CINC
CinCor Pharma, Inc. [CINC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CINC Stock Summary
In the News
CINC Financial details
Company Rating
-
Market Cap
1.27B
Income
-93.31M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
19
Optionable
No
Shortable
Yes
Earnings
03 Nov 2022
P/E
-19.81
Forward P/E
-
PEG
-1.18
P/S
-
P/B
2.29
P/C
-
P/FCF
-24.25
Quick Ratio
51.32
Current Ratio
51.96
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.55
EPS next Y
-
EPS next Q
-
EPS this Y
49.47%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-11.11%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-11%
ROE
-16%
ROC
-0.11%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
10.53-43.15
52W High
-32.42%
52W Low
+190.6%
RSI
-
Rel Volume
-
Avg Volume
625.75K
Volume
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-0.48%
-
-
-
-
Beta
-
-
-
Volatility
0.06%, 0.06%
Prev Close
0%
Price
29.06
Change
-0.38%
Company Profile
- Volume Average 625.75K
- Market Capitalization 1.27B
- Employee 19
- CEO Mr. Marc M. P. de Garidel
- Headquarters Boston,MA,US
- IPO Date 2022-01-07
-
Website
https://www.cincor.com 
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
